ATE357256T1 - Arzneimittel zur behandlung von störungen des zirkadianen rhythmus - Google Patents

Arzneimittel zur behandlung von störungen des zirkadianen rhythmus

Info

Publication number
ATE357256T1
ATE357256T1 AT03734884T AT03734884T ATE357256T1 AT E357256 T1 ATE357256 T1 AT E357256T1 AT 03734884 T AT03734884 T AT 03734884T AT 03734884 T AT03734884 T AT 03734884T AT E357256 T1 ATE357256 T1 AT E357256T1
Authority
AT
Austria
Prior art keywords
circadian rhythm
rhythm disorders
bmal1
jnk3
agent
Prior art date
Application number
AT03734884T
Other languages
English (en)
Inventor
Hirofumi Doi
Naoya Wada
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Application granted granted Critical
Publication of ATE357256T1 publication Critical patent/ATE357256T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Pathology (AREA)
AT03734884T 2002-01-31 2003-01-30 Arzneimittel zur behandlung von störungen des zirkadianen rhythmus ATE357256T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002022857 2002-01-31

Publications (1)

Publication Number Publication Date
ATE357256T1 true ATE357256T1 (de) 2007-04-15

Family

ID=27654433

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03734884T ATE357256T1 (de) 2002-01-31 2003-01-30 Arzneimittel zur behandlung von störungen des zirkadianen rhythmus

Country Status (7)

Country Link
US (1) US20050037449A1 (de)
EP (1) EP1479396B1 (de)
JP (1) JPWO2003063907A1 (de)
AT (1) ATE357256T1 (de)
CA (1) CA2474689A1 (de)
DE (1) DE60312656T2 (de)
WO (1) WO2003063907A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900936B1 (fr) * 2006-05-15 2013-01-04 Exonhit Therapeutics Sa Procede et methodes de detection de la maladie d'alzheimer
TW201605436A (zh) * 2013-08-27 2016-02-16 Suntory Holdings Ltd 時鐘基因的表現量調整劑
US11583226B2 (en) * 2020-01-05 2023-02-21 Kelly Huang Method and system of monitoring and alerting patient with sleep disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6943000B2 (en) * 1997-10-03 2005-09-13 University Of Massachusetts JNK3 modulators and methods of use
AU1184800A (en) * 1998-11-24 2000-06-13 Kyowa Hakko Kogyo Co. Ltd. Novel polypeptide
ATE407132T1 (de) * 2000-12-05 2008-09-15 Vertex Pharma Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen

Also Published As

Publication number Publication date
CA2474689A1 (en) 2003-08-07
US20050037449A1 (en) 2005-02-17
WO2003063907A1 (fr) 2003-08-07
EP1479396B1 (de) 2007-03-21
EP1479396A4 (de) 2005-08-03
DE60312656T2 (de) 2007-11-29
EP1479396A1 (de) 2004-11-24
DE60312656D1 (de) 2007-05-03
JPWO2003063907A1 (ja) 2005-05-26

Similar Documents

Publication Publication Date Title
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE60330485D1 (de) Zur behandlung von diabetes
ATE157005T1 (de) Verwendung von sertindol zur behandlung von schizophrenie
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
NO2007010I1 (no) Sitagliptin, eventuelt i form av et farmasoytisk akseptabelt salt
DE60329533D1 (de) Cyclische sulfamide zur inhibierung von gamma-sekretase
ATE368031T1 (de) Neue gamma secretase inhibitoren
ATE202346T1 (de) Benzofuran derivate und ihre verwendung als inhibitoren der knochenresorption
ATE447574T1 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE309797T1 (de) Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
DE60211746D1 (de) Aminosäurederivate zur behandlung der alzheimer-krankheit
DE69925270D1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE357256T1 (de) Arzneimittel zur behandlung von störungen des zirkadianen rhythmus
DE60111620D1 (de) Aktiviertes protein c zur behandlung von pankreatitis
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
DE69230790D1 (de) Arzneimittel zur Behandlung von durch Babesia verursachten Protozoeninfektionen
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties